Disability Around News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Disability Around. Real-time updates on events, politics, business and more.

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

March 13, 2024

TORONTO--(BUSINESS WIRE)--Mar 13, 2024--

United States United Kingdom Doug Drysdale Gabriel Fahel Samir Inamdar Health Canada

Source: valdostadailytimes.com

Researchers at Fermata to Study SAINT Neuromodulation for Treatment-Resistant Major Depression

October 25, 2023

/PRNewswire/ -- Fermata, an outpatient psychiatric center of excellence, today announced a new clinical trial to study the SAINT™ Neuromodulation System for...

United States Owen Scott Muir Carlene Macmillan World Health Organization Neuromodulation System Depressive Disorder

Source: prnewswire.com

U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder

December 17, 2022

- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive...

United Kingdom United States Treasure Island Liz Shea Mabel Martinez Thomas Hudson

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Disability Around News Today

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Researchers at Fermata to Study SAINT Neuromodulation for Treatment-Resistant Major Depression

U.S. FDA Approves VRAYLAR&#xAE; (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder

Explore More Categories

U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder